Clinical Trial Update: Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3

View source ↗

Summary

MeiraGTx reported a long-term follow-up for a CNGB3/CNGA3 gene therapy in Achromatopsia; the trial was terminated and results were posted in June 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achromatopsia

Drugs mentioned

• CNGB3/CNGA3 Achromatopsia Gene Therapy

Snippet

Sponsor: MeiraGTx UK II Ltd | Conditions: Achromatopsia | Status: TERMINATED | Results posted: 2025-06-11